Cover Image

Personalized functional profiling using ex-vivo patient-derived spheroids points out the potential of an antiangiogenic treatment in a patient with a metastatic lung atypical carcinoid: bedside-to-bench report

Lung carcinoids are neuroendocrine tumors representing 1 to 2% of lung cancers. This study outlines the case of a patient with a metastatic lung atypical carcinoid who presented with a pleural effusion and progression of liver metastases after developing resistance to conventional treatments. Person...

Full description

Saved in:
Bibliographic Details
Main Authors: Kim, Hi Chul (Author) , El-Khoury, Victoria (Author) , Schulte, Nadine (Author) , Zhan, Tianzuo (Author) , Betge, Johannes (Author) , Cousin, Loic (Author) , Felli, Emanuele (Author) , Pessaux, Patrick (Author) , Ogier, Arnaud (Author) , Opitz, Oliver (Author) , Ku, Bosung (Author) , Ebert, Matthias (Author) , Kwon, Yong-Jun (Author)
Format: Article (Journal)
Language:English
Published: 22 Feb 2022
In: Cancer biology & therapy
Year: 2022, Volume: 23, Issue: 1, Pages: 96-102
ISSN:1555-8576
DOI:10.1080/15384047.2021.2021042
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1080/15384047.2021.2021042
Verlag, kostenfrei, Volltext: https://www.tandfonline.com/doi/full/10.1080/15384047.2021.2021042
Get full text
Author Notes:Hichul Kim, Victoria El-Khoury, Nadine Schulte, Tianzuo Zhan, Johannes Betge, Loic Cousin, Emanuele Felli, Patrick Pessaux, Arnaud Ogier, Oliver G Opitz, Bosung Ku, Matthias P Ebert, and Yong-Jun Kwon
Description
Summary:Lung carcinoids are neuroendocrine tumors representing 1 to 2% of lung cancers. This study outlines the case of a patient with a metastatic lung atypical carcinoid who presented with a pleural effusion and progression of liver metastases after developing resistance to conventional treatments. Personalized functional profiling (PFP), i.e. drug screening, was performed in ex-vivo spheroids obtained from the patient’s liver metastasis to identify potential therapeutic options. The drug screening results revealed cediranib, an antiangiogenic drug, as a hit drug for this patient, from a library of 66 Food and Drug Administration (FDA)-approved and investigational drugs. Based on the PFP results and the reported evidence of clinical efficacy of bevacizumab and capecitabine combination in gastro-intestinal neuroendocrine tumors, this combination was given to the patient. Four months later, the pleural effusion and pleura carcinosis regressed and the liver metastasis did not progress. The patient experienced 2 years of a stable disease under the PFP-guided personalized treatment.
Item Description:Gesehen am 13.06.2023
Physical Description:Online Resource
ISSN:1555-8576
DOI:10.1080/15384047.2021.2021042

Similar Items